- Home
- ANEB vs CTXR Comparison
ANEB vs CTXR Comparison
Compare ANEB & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- CTXR
- Stock Information
- Founded
- ANEB 2020
- CTXR 2007
- Country
- ANEB United States
- CTXR United States
- Employees
- ANEB N/A
- CTXR N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- CTXR Biotechnology: Pharmaceutical Preparations
- Sector
- ANEB Health Care
- CTXR Health Care
- Exchange
- ANEB Nasdaq
- CTXR Nasdaq
- Market Cap
- ANEB 79.9M
- CTXR 84.9M
- IPO Year
- ANEB 2021
- CTXR N/A
- Fundamental
- Price
- ANEB $1.93
- CTXR $0.38
- Analyst Decision
- ANEB Buy
- CTXR Strong Buy
- Analyst Count
- ANEB 1
- CTXR 2
- Target Price
- ANEB $8.00
- CTXR $5.00
- AVG Volume (30 Days)
- ANEB 13.3K
- CTXR 1.1M
- Earning Date
- ANEB 11-12-2024
- CTXR 08-12-2024
- Dividend Yield
- ANEB N/A
- CTXR N/A
- EPS Growth
- ANEB N/A
- CTXR N/A
- EPS
- ANEB N/A
- CTXR N/A
- Revenue
- ANEB N/A
- CTXR N/A
- Revenue This Year
- ANEB N/A
- CTXR N/A
- Revenue Next Year
- ANEB N/A
- CTXR N/A
- P/E Ratio
- ANEB N/A
- CTXR N/A
- Revenue Growth
- ANEB N/A
- CTXR N/A
- 52 Week Low
- ANEB $1.72
- CTXR $0.34
- 52 Week High
- ANEB $3.30
- CTXR $1.07
- Technical
- Relative Strength Index (RSI)
- ANEB 49.10
- CTXR 34.70
- Support Level
- ANEB $1.83
- CTXR $0.36
- Resistance Level
- ANEB $1.96
- CTXR $0.42
- Average True Range (ATR)
- ANEB 0.08
- CTXR 0.04
- MACD
- ANEB 0.00
- CTXR 0.00
- Stochastic Oscillator
- ANEB 49.09
- CTXR 32.37
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.